A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...

88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON trial in ...

A decade into reformulating Pfizer’s oral renal cell carcinoma drug Inlyta (axitinib) into a treatment that can be injected ...

The study, presented at the American Academy of Ophthalmology (AAO) Annual meeting, reported that 88% of patients treated with EYLEA HD were maintained on a dosing interval of 12 weeks or more at ...

Two billion dollars in investments. 4,500 employees. Regeneron has grown into a major economic engine — and it's now ...

Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $1,050 from $1,200 and keeps an Overweight rating on the shares. Given ...

Moreover, in the second quarter sales of EYLEA and EYLEA HD came in with a 2% increase year-over-year to $1.53 billion. The overall revenue of the company was $3.55 billion, up 12% during the same ...

TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) today shared positive results from a three-year extension study of the Phase 3 PHOTON trial, demonstrating that EYLEA HD ...

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an ...